Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

EGFR exon 20 abstracts at ASCO 2019 per iPlanner

New Options for EGFR Exon 20 and HER2 Mutations

John Heymach, MD, PhD - Speaker
The University of Texas MD Anderson Cancer Center

8:15 AM - 8:30 AM on June 1st

and of pozi's competition on June 3rd

Abstract 9007
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

Pasi A. Janne, MD, PhD - First Author
Dana-Farber Cancer Institute

At WCWL 2018 pozi had a 55% ORR and PFS of 5.5m for 44 patients whereas TAK-788 had an ORR of 38% for 18 patients. And several more on June 2nd

Poster Board: #366 • Abstract 9043
Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

Yan Wang - First Author
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Poster Board: #386 • Abstract 9063
Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.

Sai-Hong Ignatius Ou, MD, PhD - First Author
Chao Family Comprehensive Cancer Center, University of California